Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,128 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Dravet Syndrome
Interventions: LP352, Placebo; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Cancer
Interventions: Internet-based pain coping skills program; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 149
States / cities: Fort Smith, Arkansas • Antioch, California • Dublin, California + 118 more

Conditions: HIV Infections
Interventions: Tenofovir disoproxil fumarate; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Foot Ulcer, Diabetic
Interventions: Medical Food, Drink mix calorically similar to experimental product; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Brawley, California + 38 more

Conditions: Atherosclerosis
Interventions: Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent; Device
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 40
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 36 more

Conditions: Insomnia, Depression
Interventions: Digital CBT-I, Digital SHE; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Dependency, HIV Infections
Interventions: Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions: TN-401; Genetic
Lead sponsor: Tenaya Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more

Conditions: Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
Interventions: Vismodegib, Radiation therapy; Drug · Radiation
Lead sponsor: Sue Yom; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: HAART Non-Adherence, HIV, HIV Infections
Interventions: Cell Phone Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 24 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 2 more

Conditions: Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions: Letrozole (Femara), Letrozole; Avastin; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more

Conditions: Acne
Interventions: Acne mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 79
States / cities: Scottsdale, Arizona • Cerritos, California • Encino, California + 64 more

Conditions: Gender Affirmation Surgery, Perioperative Care, Transgender Health
Interventions: STRIVE Peer Support Intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Detroit, Michigan + 6 more

Conditions: Pulmonary Disease, Chronic Obstructive, Obesity, Weight Loss, Life Style, Overweight
Interventions: Lifestyle Intervention; Behavioral
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 40 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 39
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 32 more

Conditions: Contraception, Sexually Transmitted Diseases
Interventions: computer-assisted provision of hormonal contraception, STI module; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 814 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Diabetes
Interventions: Live Well, Be Well; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 25 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions: Tovorafenib; Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 39 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Acanthamoeba Keratitis
Interventions: Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo; Drug · Other
Lead sponsor: Jeremy Keenan, MD, MPH; Other
Eligibility: 8 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Tampa, Florida + 5 more

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Telephone-Based exercise intervention; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Breast Cancer
Interventions: Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 3,509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 393
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more

Conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1201
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more

Conditions: COVID-19, Pneumonia, Viral
Interventions: Lung Ultrasound; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: San Francisco, California • Stanford, California

Conditions: Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions: radiation therapy, surgery, mFOLFIRINOX, FOLFOX; Radiation · Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 154
States / cities: Mobile, Alabama • Antioch, California • Berkeley, California + 122 more

Search by objective public record fields.

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

An Internet-based Program to Help Cancer Survivors Manage Pain

The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients

Evaluation of a Medical Food for Chronic Wounds

IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Perinatal Research on Improving Sleep and Mental Health

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

Cell Phone Reminders Intervention

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

Support for Transgender and Non-Binary Individuals Seeking Vaginoplasty Study

INtervention Study In overweiGHT Patients With COPD

Computer-Assisted Provision of Reproductive Health Care

Reducing Disparities in Diabetes Risk Through Lifestyle Changes in Community Settings

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Parasitic Ulcer Treatment Trial

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

The Active After Cancer Trial (AACT)

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Predicting Outcomes for Covid-19 Using Sonography

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer